Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening
2017/09/27 by Mark Schiffman, Walter K Kinney, Walter Kinney +16 · 25 citations
Medicine · Decision Sciences · #Cervical Cancer and HPV Research #Endometrial and Cervical Cancer Treatments #Reliability and Agreement in Measurement
paper · pdf · doi:10.1093/jnci/djx225
Abstract
Background: The main goal of cervical screening programs is to detect and treat precancer before cancer develops. Human papillomavirus (HPV) testing is more sensitive than cytology for detecting precancer. However, reports of rare HPV-negative, cytology-positive cancers are motivating continued use of both tests (cotesting) despite increased testing costs. Methods: We quantified the detection of cervical precancer and cancer by cotesting compared with HPV testing alone at Kaiser Permanente Northern California (KPNC), where 1 208 710 women age 30 years and older have undergone triennial cervical cotesting since 2003. Screening histories preceding cervical cancers (n = 623) and precancers (n = 5369) were examined to assess the relative contribution of the cytology and HPV test components in identifying cases. The performances of HPV testing and cytology were compared using contingency table methods, general estimating equation models, and nonparametric statistics; all statistical tests were two-sided. Results: HPV testing identified more women subsequently diagnosed with cancer (P < .001) and precancer (P < .001) than cytology. HPV testing was statistically significantly more likely to be positive for cancer at any time point (P < .001), except within 12 months (P = .10). HPV-negative/cytology-positive results preceded only small fractions of cases of precancer (3.5%) and cancer (5.9%); these cancers were more likely to be regional or distant stage with squamous histopathology than other cases. Given the rarity of cancers among screened women, the contribution of cytology to screening translated to earlier detection of at most five cases per million women per year. Two-thirds (67.9%) of women found to have cancer during 10 years of follow-up at KPNC were detected by the first cotest performed. Conclusions: The added sensitivity of cotesting vs HPV alone for detection of treatable cancer affected extremely few women.
Cited by
- The Intersection of HPV Epidemiology, Genomics and Mechanistic Studies of HPV-Mediated Carcinogenesis. [europepmc]
- Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology. [europepmc]
- Molecular mechanisms of the preventable causes of cancer in the United States. [europepmc]
- High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study. [europepmc]
- Cervical screening and risk of adenosquamous and rare histological types of invasive cervical carcinoma: population based nested case-control study. [europepmc]
- Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany. [europepmc]
- Three large scale surveys highlight the complexity of cervical cancer under-screening among women 45-65years of age in the United States. [europepmc]
- Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review. [europepmc]
- Evaluation of multiple screening methods for cervical cancers in rural areas of Xinjiang, China. [europepmc]
- 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. [europepmc]
- Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States. [europepmc]
- Screening for Cervical Cancer. [europepmc]
- Automatic model for cervical cancer screening based on convolutional neural network: a retrospective, multicohort, multicenter study. [europepmc]
- Summary of Current Guidelines for Cervical Cancer Screening and Management of Abnormal Test Results: 2016-2020. [europepmc]
- Effect of introducing human papillomavirus genotyping into real-world screening on cervical cancer screening in China: a retrospective population-based cohort study. [europepmc]
- Updated evidence-based recommendations for cervical cancer screening in France. [europepmc]
- Understanding COVID-19 impact on cervical, breast, and colorectal cancer screening among federally qualified healthcare centers participating in "Back on track with screening" quality improvement projects. [europepmc]
- The IARC Perspective on Cervical Cancer Screening. [europepmc]
- Prognostic impact of human papillomavirus infection on cervical dysplasia, cancer, and patient survival in Saudi Arabia: A 10-year retrospective analysis. [europepmc]
- False Negative Results in Cervical Cancer Screening-Risks, Reasons and Implications for Clinical Practice and Public Health. [europepmc]
- Use of Single Cell Transcriptomic Techniques to Study the Role of High-Risk Human Papillomavirus Infection in Cervical Cancer. [europepmc]
- Comparison of primary cytology, primary HPV testing and co-testing as cervical cancer screening for Chinese women: a population-based screening cohort. [europepmc]
- Prevalence of HPV and Assessing Type-Specific HPV Testing in Cervical High-Grade Squamous Intraepithelial Lesions in Poland. [europepmc]
- Strategies to eliminate cervical cancer in China. [europepmc]
- Validation in Zambia of a cervical screening strategy including HPV genotyping and artificial intelligence (AI)-based automated visual evaluation. [europepmc]
Related